Featured primary antibody - Claudin 18.2-IHC Series-LBP SYSTEM

CN EN

PRODUCTS

HOME> PRODUCTS>

Featured primary antibody - Claudin 18.2

Antibody Name: Claudin18.2
Product Number: LBP-IHC(M). M498-4-E
Clone Number: 43-14A
Isotype: Mouse Monoclonal Antibody
Cellular Localization: Cell Membrane
Applicable Tissues: Paraffin-embedded / Frozen
Positive Control: Gastric Cancer
Antibody Incubation Time: 60 min
Antigen Retrieval: Heat-induced Epitope Retrieval (TrisEDTA)

Clinical Significance

Claudin-18.2 is a subtype of the tight junction protein family. In normal tissues, it is exclusively expressed in differentiated gastric mucosal epithelial cells, not in gastric stem cells, and is barely expressed in other normal tissues. However, it is highly expressed in various tumor tissues, such as gastric cancer (60%-80%), pancreatic cancer (50%), esophageal cancer (30%-50%), and lung cancer (40%-60%). Even in metastatic lesions of gastric cancer, Claudin-18.2 remains highly expressed.

The recommendation level of Claudin-18.2 detection in the CSCO guidelines has been upgraded from Grade II (Category 2A) to Grade I (Category 1B), highlighting its important role in gastric cancer diagnosis. The LBP SYSTEM's Claudin-18.2 clone 43-14A has shown a high consistency with 43-14A (Ventana) on Ventana, Leica, and Dako platforms. This consistency, with both negative and positive concordance rates reaching 100%, has been included in the first consensus on Claudin-18.2 detection.

Interpretation of any results should be performed by pathologists in combination with pathological morphology, clinical manifestations, and other detection methods, and it should not be used as a standalone diagnostic indicator.

Reference:

[1]《胃癌Claudin18.2临床检测专家共识（2025版）》专家委员会. 胃癌Claudin18.2临床检测专家共识（2025版）[J]. 中华病理学杂志,2025,54(07)：718-725.

[2]2025版CSCO胃癌诊疗指南

[3]S. Ni, W. Sheng, W. Su, et al. 159P Better performance of pan - claudin18 antibodies on claudin18.2 detection in gastric adenocarcinoma than claudin18.2 specific antibody[J]. Annals of Oncology, 2023, 34: S244 - S245.

[4].Shitara K, Lordick F, Bang YJ, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial [published correction appears in Lancet. 2023 Jul 22;402(10398):290.

[5].Shah MA, Shitara K, Ajani JA, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29(8):2133-2141.

[6].Jasani B, Taniere P, Schildhaus HU, et al. Global Ring Study to Investigate the Comparability of Total Assay Performance of Commercial Claudin 18 Antibodies for Evaluation in Gastric Cancer. Lab Invest.

ONLINE MESSAGE

Please enter your contact information and we will get back to you as soon as possible.